Last reviewed · How we verify
Nicotine patch, nicotine inhaler, bupropion
This combination therapy uses nicotine replacement (patch and inhaler) plus bupropion to reduce nicotine cravings and withdrawal symptoms while addressing the neurochemical basis of nicotine dependence.
This combination therapy uses nicotine replacement (patch and inhaler) plus bupropion to reduce nicotine cravings and withdrawal symptoms while addressing the neurochemical basis of nicotine dependence. Used for Nicotine dependence / smoking cessation.
At a glance
| Generic name | Nicotine patch, nicotine inhaler, bupropion |
|---|---|
| Sponsor | University of Medicine and Dentistry of New Jersey |
| Drug class | Smoking cessation agent combination |
| Target | Nicotinic acetylcholine receptors (nicotine); dopamine and norepinephrine transporters (bupropion) |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicotine patch and inhaler provide direct nicotinic receptor agonism to satisfy physical dependence and reduce withdrawal. Bupropion, an atypical antidepressant, inhibits reuptake of dopamine and norepinephrine, addressing the reward pathway disruption that occurs during smoking cessation and reducing psychological cravings. Together, they target both the physical and behavioral components of nicotine addiction.
Approved indications
- Nicotine dependence / smoking cessation
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Seizures (bupropion)
- Skin irritation at patch site
Key clinical trials
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Metabolism-informed Care for Smoking Cessation (NA)
- A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (PHASE4)
- The Precision CAD Trial (NA)
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care (PHASE4)
- Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: